Amgen 2007 Annual Report Download - page 37

Download and view the complete annual report

Please find page 37 of the 2007 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 180

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180

Additionally, Aranesp®competes internationally with other companies’ marketed products to treat anemia
associated with CRF. The following table reflects other companies and their currently marketed products that
primarily compete with Aranesp®in the United States and internationally in the nephrology segment.
Amgen Marketed Product Competitor Marketed Product Competitor
Aranesp®— U.S. PROCRIT®(1) J&J
Aranesp®— International EPREX®/ ERYPO®Janssen-Cilag
Aranesp®— International NeoRecormon®Roche
Aranesp®— International MIRCERA®(2) Roche
Aranesp®— International Dynepo®Shire Pharmaceutical Group Plc
(“Shire”)
Aranesp®— International Retacrit™(3) / Silapo®(3) Hospira / Stada
Aranesp®— International Binocrit®(3) / Epoetin Alpha
Hexal®(3) / Abseamed®(3)
Sandoz /Hexal /Medice
(1) In the United States, Aranesp®competes with PROCRIT®in the pre-dialysis setting.
(2) Approved by the European Commission in July 2007 and launched in certain EU countries shortly thereafter.
(3) Biosimilar products that were approved and launched in certain EU countries in 2007.
In addition to competition from the above-noted products, Affymax/Takeda are co-developing, Hematide™,
an erythropoietin mimetic for the treatment of anemia.
Any products or technologies that are directly or indirectly successful in treating secondary hyper-
parathyroidism in patients with CKD on dialysis could negatively impact product sales for Sensipar®/Mimpara®.
Amgen Marketed Product Competitor Marketed Product Competitor
Sensipar®— U.S. Zemplar®Abbott Laboratories (“Abbott”)
Sensipar®— U.S. Hectorol®Genzyme Corporation
Sensipar®— U.S. Rocaltrol®Roche
Mimpara®— International Zemplar®Abbott
Inflammatory disease
Any products or technologies that are directly or indirectly successful in treating moderate to severe rheuma-
toid arthritis, moderate to severe juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and
moderate to severe plaque psoriasis could negatively impact product sales for ENBREL. Current treatments for
these indications include generic methotrexate and other products.
The following table reflects companies and their currently marketed products that primarily compete with
ENBREL in the United States and Canada in the inflammatory disease setting.
Amgen Marketed Product Competitor Marketed Product Competitor
ENBREL — U.S. & Canada REMICADE®Centocor, Inc.(1) / Schering Plough
Corporation
ENBREL — U.S. & Canada HUMIRA®Abbott
ENBREL — U.S. & Canada Raptiva®Genentech
ENBREL — U.S. & Canada Amevive®Biogen IDEC Inc. (“Biogen”)
ENBREL — U.S. & Canada Orencia®Bristol-Myers Squibb Corporation
(“BMS”)
ENBREL — U.S. & Canada Neoral®Novartis
ENBREL — U.S. & Canada Arava®Sanofi-Aventis
ENBREL — U.S. & Canada Rheumatrex®DAVA Pharmaceuticals, Inc.
ENBREL — U.S. & Canada Trexall™ Duramed Pharmaceuticals, Inc.(2)
ENBREL — U.S. & Canada Rituxan®Genentech
ENBREL — U.S. & Canada Soriatane®Connetics Corporation(3)
(1) A subsidiary of J&J.
(2) A subsidiary of Barr Pharmaceuticals, Inc.
(3) A subsidiary of Stiefel Laboratories, Inc.
25